Cullinan Oncology Entered into an Exclusive License with Harbour BioMed to Develop and Commercialize HBM7008 (CLN-418) in the US
Shots:
- Harbour BioMed to receive a $25M up front license fee for the exclusive right to develop & commercialize CLN-418/HBM7008 in the US, ~$148M in development & regulatory milestones, $415M in sales-based milestones along with royalties on US commercial sales
- The agreement advances Cullinan Oncology’s diversified portfolio with the addition of CLN-418. The agreement also adds another clinical-stage asset to its portfolio
- CLN-418/HBM7008, a B7H4 x 4-1BB bispecific immune activator developed from the next- HCAb-based multi-specific Ab discovery platform HBICE & is being studied in the P-I trial evaluating the safety, tolerability, PK & anti-tumor activity in ~108 patients with advanced solid tumors at US & Australian sites
Ref: GlobeNewswire | Image: Harbour BioMed
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
